Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LFM-A13 是一种 BTK,JAK2,PLK 有效抑制剂,可抑制 BTK、Plx1 和 PLK3 的活性,IC50分别为 2.5、10 和 61 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 193 | 现货 | ||
5 mg | ¥ 460 | 现货 | ||
10 mg | ¥ 671 | 现货 | ||
25 mg | ¥ 1,365 | 现货 | ||
50 mg | ¥ 2,682 | 现货 | ||
100 mg | ¥ 3,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 462 | 现货 |
产品描述 | LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK. |
靶点活性 | BTK:2.5 μM |
体外活性 | In BTK+ B-lineage leukemic cells, LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. [1] In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels [2] In human neutrophils, LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity. [3] |
体内活性 | In BALB/c mice bearing BCL-1 leukemia, combination of LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. [2] In primary myeloma-bearing SCID-rab mice, LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth. [4] |
分子量 | 360 |
分子式 | C11H8Br2N2O2 |
CAS No. | 244240-24-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 67 mg/mL (186.1 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7778 mL | 13.8889 mL | 27.7778 mL | 69.4444 mL |
5 mM | 0.5556 mL | 2.7778 mL | 5.5556 mL | 13.8889 mL | |
10 mM | 0.2778 mL | 1.3889 mL | 2.7778 mL | 6.9444 mL | |
20 mM | 0.1389 mL | 0.6944 mL | 1.3889 mL | 3.4722 mL | |
50 mM | 0.0556 mL | 0.2778 mL | 0.5556 mL | 1.3889 mL | |
100 mM | 0.0278 mL | 0.1389 mL | 0.2778 mL | 0.6944 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LFM-A13 244240-24-2 Angiogenesis Cell Cycle/Checkpoint Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors PLK JAK BTK Janus kinase LFM-A-13 Inhibitor LFMA13 Polo-like Kinase (PLK) Bruton tyrosine kinase Btk LFM A13 inhibit inhibitor